Disease Extent at Secondary Cytoreductive Surgery is Predictive of Progression-free and Overall Survival in Advanced Stage Ovarian Cancer: an NRG Oncology/Gynecologic Oncology Group study

PURPOSE: GOG 152 was a randomized trial of secondary cytoreductive surgery (SCS) in patients with suboptimal residual disease (residual tumor nodule >1 cm in greatest diameter) following primary cytoreductive surgery for advanced stage ovarian cancer. The current analysis was undertaken to evalua...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Gynecol Oncol
Autori principali: Rose, Peter G., Java, James J., Morgan, Mark A., Secord, Angeles Alvarez, Kesterson, Joshua P., Stehman, Frederick B., Warshal, David P., Creasman, William T., Hanjani, Parviz, Morris, Robert T., Copeland, Larry J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2016
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5720165/
https://ncbi.nlm.nih.gov/pubmed/27692669
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2016.09.005
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi